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ABSTRACT 
Metformin/Gliclazide niosomes were formulated with span 60 by ether injection method. 
Three batches MG1-MG3 were prepared in order to study influence of drug polymer ratio on 
the niosomes formation and in vitro drug release. The formulated niosomes were 
characterized by drug entrapment, vesicle size determination, and in vitro drug release. 
Optimized concentration of span 60 and cholesterol was found to be 1:1. In the in-vitro study, 
niosomes formulation of MG1 showed high percentage of drug release, 40.18 to 45.75% for 
about 8 hrs. This indicated that this batch of niosomes formulation exhibit sustained drug 
release pattern as the niosomes act as reservoir system for continuous delivery of drug. The 
quantity of Metformin/Gliclazide present in the niosomes and the release medium were 
estimated by a validated HPLC method. The formulated niosomes had acceptable 
physicochemical characters and released the drug over 6-8 h. The data obtained from in vitro 
release studies were fitted with various kinetic models and was found to follow Higuchi 
kinetics. 
 
Introduction
Diabetes is a disease with skyrocketing prevalence. The 
number of ~280 million patients today will increase to ~450 
million in 2030. Therefore, new approaches to research and 
development (R&D) in the pharmaceutical industry are needed 
in how we work and what we work upon [1]. Metformin 
hydrochloride and Gliclazide are oral hypoglycemic agents 
belonging to biguanide group and second generation sulphonyl 
urea, respectively (Fig. 1). Generally, they are individually 
used in the treatment of type II non-insulin dependent diabetes 
mellitus [2]. The combinations of both the drugs are more 
effective than individual therapy. Metformin acts by 
decreasing hepatic glucose production and improves insulin 
sensitivity by increasing peripheral glucose uptake. Because of 
its shorter and variable biological half-life of 1.5-4.5 h, it 
should be repeatedly administered (500 mg thrice a day) to 
maintain effective plasma concentration. Gliclazide reduces 
the glucose level by direct stimulation of insulin release from 
beta cells of pancreatic islet. Relatively Gliclazide is having 
longer biological half-life (6-15 h) depending upon individual 
and the dose is 80 mg two-three times a day with meals. 
Combination of Metformin-500 mg and Gliclazide-80 mg per 
tablet is available in India and it is to be taken two to three 
times a day to get required effect [3, 4]. Recently, lipid and 
nonionic surfactant based drug delivery systems specifically 
niosomes have drawn much attention from researchers as 
potential carriers of various bioactive molecules that could be 
used for therapeutic applications. Several commercial 
niosome-based drugs have already been marketed with a great 
success [5,6].In the present study, we attempted to formulate 
Metformin/Gliclazide dual drug loaded niosomes by using 
span 60 and cholesterol, with an intention to extend the drug 
release over a period of 8-12 h, hence it can be taken once a 
day. The formulations were analysed for drug content by a 
validated HPLC technique developed in our laboratory and 
characterized by various physicochemical parameters such as 
drug entrapment, vesicle size, and in vitro drug release. 
 
Fig 1: Representative structure of anti-diabetic drugs  
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Materials and Methods 
Chemicals 
Span 60 (sorbitanemonoesterate, CDH lab reagent), 
Cholesterol (LOBA CHEME), Amoxycillin drug (Zydus 
Cadila), Chloroform (Ramkem), Phosphate Buffer Saline (pH 
7.4), 0.1 N Hydrochloric acid, 0.1 N Sodium Hydroxide, 
Sodium Sulfate, Sulfuric acid, 0.1 N Glacial Acetic acid, 
Ammonium Hydroxide, Sodium Chloride, Ethanol, Methanol, 
Acetone, Dialysis membrane (LA390-60), Nutrient Agar and 
Dialysis membrane were from Hi Media.  
Instruments 
Hot air oven (Scientech,325 L), Incubator (Scientech), Digital 
Balance (Denver, Germany), Autoclave vertical, Laminar air 
flow chamber horizontal (Scientech), Shimadzu 1800 Double 
Beam UV-VIS Spectrophotometer (Japan), Centrifuge (Remi 
C-24 India), Vortex Mixer (Remi), Magnetic stirrer with hot 
plate (Remi), Digital pH meter (Eutech, Singapore), Vacuum 
Rotary Evaporator (Buchi Type), Trinocular Microscope 
(Olympus CH 20 I) with Ocular Micrometre. 
Preparation of   niosomes 
Ether injection method: A mixture of Span 60 and cholesterol 
in different ratio was added to a beaker containing 10 ml 
diethyl ether organic solvent. To this mixture, 250 mg of 
amoxycillin was added portion wise with continuous stirring 
and maintaining a temperature of 30 ºC. This heated solution 
was finally filled in a 20 mL syringe. A solution 125 mg 
clavulanic acid dissolved in 10 mL phosphate-buffered saline 
was prepared separately. The contents of the syringe were 
injected drop wise into a mixture with continuous stirring [7]. 
 
 
 
IR Spectroscopy 
Fourier transform infrared spectroscopy has been used to 
study the purity of API. The standard amoxicillin and API 
sample were mixed separately with IR grade KBr and were 
scanned over a range of 400-4000 cm
−1
 using FTIR instrument 
(FTIR-1700, Shimadzu, Kyoto, Japan). 
HPLC 
Stock solution of Amoxicillin was prepared by dissolving 20 
mg of Amoxicillin in 200 ml standard volumetric flask 
containing approximately 200 ml of buffer solution and the 
solution was sonicated for 20 min and then the volume was 
made upto the mark with mobile phase. Subsequent dilutions 
of 2 ml to 20 ml this  solution were made with mobile phase. 
The standard solutions prepared as above were injected into 
the 10 μL loop and the chromatogram was recorded.  
Chromatographic condition: 
Mobile phase: [ACN]: [Buffer]:: 4:96 
Flow Rate: 1.5 ml/min 
Spectrophotometer: 230 nm 
Injection volume: 10 μL 
 
Results and Discussion 
 
Niosomal formulations of metformin- gliclazide were 
prepared with Span 60 
as surfactants. Span 60 yields very stable niosomes with a 
narrow particle size distribution but they exhibit rather low 
entrapment efficiency. By adding cholesterol to surfactant in a 
1:1 weight ratio both stability and entrapment efficiency 
increased. In addition, surface of Span 60 niosomes is flexible 
due to their head group structure. 
Table 1: Formulation of Niosomes 
 
S. No. Formulation Code Span 60 Cholesterol Solvent Drugs 
1. MG1 50 mg 50 mg 10 mL DEA 500 mg metformin + 60 mg gliclazide 
2 MG2 50 mg 100 mg 10 mL DEA 500 mg metformin + 60 mg gliclazide 
3 MG3 100 mg 50 mg 10 mL DEA 500 mg metformin + 60 mg gliclazide 
Dynamic laser scattering was performed to characterize the size of the MG1, MG2 and MG3 niosomal formula. The formula showed 
small micro-vesicular size (8.15-10.50 μm) (Fig. 2). It was also really worth to mention that such micro-size ranged vesicles represent 
a good pharmaceutical carrier for passive targeting to infected cells.  
 
Fig 2: Mean particle size of niosomal formulations 
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In-vitro release 
Release data expressed as percent drug released over 8 hours 
determined for three formulations are shown in Fig. 3. The 
release profile of the free unentrapped metformin and 
gliclazide showed that 75% of the drug was released within 
one hour. In comparison, the release profile of metformin from 
the niosomal formulations showed that 40.18% of the drug 
was released in 8 hours, reflecting the sustained release of 
metformin from the niosomal formulations. Similarly, the 
release profile of gliclazide from the niosomal formulations 
showed that 45.75% of the drug was released in 8 hours. The 
results of release profiles of the binary drugs indicate the 
effect on release of the changes in proportion of free to 
niosome-entrapped drug in the prepared formulations. 
 
 
Fig 3: % Drug released of niosome formulations MG1, MG2 and MG3 
Compatibility studies 
Excipients compatibility studies the results depicts there was 
no change in color, no lump formation occurred in any of the 
mixture at different temperature & humidity conditions, when 
observed on different days (7th, 15, 30th days) interval in 
comparison to initial observation on 0th day. This confirmed 
that both the drugs were compatible with each other as well as 
with excipients. Rf values obtained from TLC studies on (7th, 
15, 30th days) were approximately similar to Rf values of pure 
drugs and niosomes obtained on 0th day, predicting the 
compatibility of both drugs with gel excipients. 
 
 
 
FT IR 
Drug excipients interaction was also checked out by 
comparing the FT IR spectra of pure drug metformin, 
gliclazide and FTIR spectra of the physical mixture of drugs 
with excipients; span 60 and cholesterol. The FT IR spectra in 
this region of metformin-gliclazide binary system, of molar 
ratio 1:1, are shown in Fig 4. Frequencies assigned to primary 
amine N-H stretching, secondary amine N-H and imino C=N 
group of metformin whereas C=O and N-H stretching of 
gliclazide, all the bands were identified in free metformin-
gliclazide and are reported in Table. IR spectra indicate no 
significant difference in characteristic peak at wave numbers 
of the drug in presence of the excipient. Thus, IR spectra 
indicated no drug-excipient interaction. 
 
Table 2: Assignment of relevant IR absorption bands of metformin-gliclazide and niosome formulation 
 
Assignment Metformin(cm
-1
) Gliclazide(cm
-1
) Formulation MG1 (cm
-1
) 
1º amine N-H 3370 - 3410 
2º amine N-H 3216 - 3200 
C=N 1678 - 1710 
N-H (amide) - 3300 3400 
C=O - 1590 1580 
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Fig 4: IR spectrum of formulation MG1 
HPLC 
The evaluation of the stability and compatibility of metformin 
and gliclazide binary mixtures with the span 60 and 
cholesterol after one month at 40°C and 75% RH was 
conducted using the HPLC-UV method described in the 
relevant USP monograph. The response was linear within the 
range studied (R² = 0.9870) (Fig. 5). The HPLC-UV method 
for quantitation of metformin and gliclazide can detect thermal 
degradation and chemical interactions with excepients, which 
decrease the concentration of drugs. The chromatograms of 
binary mixtures are shown in Figure. No alteration in peak 
area was detected, indicating that these excepients have 
sufficient compatibility for use in noisome formulation of 
metformin and gliclazide. 
 
Fig 5: HPLC chromatogram of noisome formulation 
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Conclusion 
 
Niosomes prepared from Span 60-cholesterol were able to 
encapsulate metformin and gliclazide. Average size, stability 
and RSV entrapment efficiency of niosomes are linked not 
only to their composition but also to the protocol employed in 
preparing the niosomes. Optimized concentration of span 60 
and cholesterol was found to be 1:1. In the in-vitro study, 
niosomes formulation of MG1 showed high percentage of 
drug release, 40.18 to 45.75% for about 8 hrs. This indicated 
that this batch of niosomes formulation exhibit sustained drug 
release pattern as the niosomes act as reservoir system for 
continuous delivery of drug. In stability studies, the optimized 
formulation, MG1 Stability started to deteriorate from 2
nd
 
week where the niosomes vesicles are seen in non-spherical 
shape. On 21
st
 and 28
th
 day the niosomes formulation were 
examined and seen in non-spherical shape and are clumped for 
both storage condition. This is mainly due to disruption or 
aggregation of vesicles since it is exposed to chemical 
degradation like hydrolysis and oxidation. As for the drug 
release, niosomes formulation stored in room temperature and 
refrigerated condition showed 90% which mainly due to 
membrane-stabilizing effect of cholesterol. Thus, from the 
prepared niosomes formulation, it can be concluded that the 
vesicular system was more stable at 2º C - 8º C. The released 
data of optimized niosomes formulation MG1 of amoxicillin 
were analysed mathematically according to zero order, first 
order, and Higuchi equations. As for the Higuchi’s model 
(r
2
=0.9447), First order (r
2
=0.8227), and zero order 
(r
2
=0.7577) regression co-efficient obtained. The metformin 
drug release from niosomes does not obey first order kinetics, 
which means that the release of amoxicillin from the niosomes 
vesicle is independent to concentration gradient. Similarly, for 
gliclazide regression co-efficient obtained as Higuchi’s model 
(r
2
=0.9688), First order (r
2
=0.8682), and zero order 
(r
2=0.7971). Best fitted Higuchi’s model indicates that the 
drug release by diffusion.  
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